MDMA, methamphetamine and their combination: Possible lessons for party drug users from recent preclinical research

Drug and Alcohol Review

Volumn 26, Issue 1, 2007, Pages 9-15

  Clemens, Kelly J ^a,c   McGregor, Iain S ^a   Hunt, Glenn E ^a   Cornish, Jennifer L ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Animal model; Ecstasy; MDMA; Methamphetamine; Neurotoxicity; Polydrug use; Speed

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; METHAMPHETAMINE; PSYCHEDELIC AGENT;

ADDICTION; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DISEASE MODEL; DRUG ABUSE; DRUG EFFECT; DRUG INTERACTION; DRUG SCREENING; HUMAN; PSYCHOLOGICAL ASPECT; RAT; REVIEW; SOCIAL BEHAVIOR; SUBSTANCE ABUSE;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HALLUCINOGENS; HUMANS; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; SOCIAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 33847176624     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1080/09595230601036945     Document Type: Review

References (70)

1. Hanson GR, Rau KS, Fleckenstein AE. The methamphetamine experience: a NIDA partnership. Neuropharmacology 2004;47(Suppl. 1):92-100.
2. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005;75:406-33.
3. United Nations Office on Drugs and Crime. Ecstasy and Amphetamines: Global Survey 2003. Vienna: UNODC; 2003.
4. Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW. Methamphetamine self-administration by humans. Psychopharmacology (Berl) 2001;157:75-81.
5. McKetin R, McLaren J, Kelly E. The Sydney methamphetamine market: patterns of supply, use, personal harms and social consequences: National Drug and Alcohol Research Centre, University of New South Wales: Commonwealth of Australia; 2005.
6. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005;13:141-54.
7. Baumann MH, Wang X, Rothman RB. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 2007;189:407-24.
8. Gouzoulis-Mayfrank E, Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol. 2006;20:188-93.
9. Barrett SP, Gross SR, Garand I, Pihl RO. Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse 2005;40:1525-37.
10. Degenhardt L, Agaliotis M, White B, Stafford J. New South Wales Party Drug Trends 2004: Findings from the Party Drugs Initiative (PDI), Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2005.
11. Kalasinsky KS, Hugel J, Kish SJ. Use of MDA (the 'love drug') and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci 2004;49:1106-12.
12. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41.
13. Fitzgerald JL, Reid JJ. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch Pharmacol 1993;347:313-23.
14. Tatsuta T, Kitanaka N, Kitanaka J, Morita Y, Takemura M. Effects of monoamine oxidase inhibitors on methamphetamine- induced stereotypy in mice and rats. Neurochem Res 2005;30:1377-85.
15. Parrott AC. Chronic tolerance to recreational MDMA (3,4- methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 2005;19:71-83.
16. Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 2001;16:589-98.
17. Newton TF, Roache JD, De La Garza R, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006;31: 1537-44.
18. Shearer J, Gowing LR. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev 2004;23:203-11.
19. Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 2005;18:265-70.
20. Beardsley PM, Balster RL, Harris LS. Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 1986;18:149-57.
21. Schenk S, Gittings D, Johnstone M, Daniela E. Development, maintenance and temporal pattern of selfadministration maintained by ecstasy (MDMA) in rats. Psychopharmacology (Berl) 2003;169:21-7.
22. Cornish JL, Shahnawaz Z, Thompson MR, et al. Heat increases 3,4-methylenedioxymethamphetamine selfadministration and social effects in rats. Eur J Pharmacol 2003;482:339-41.
23. Carney JM, Landrum RW, ChengMS, Seale TW. Establishment of chronic intravenous drug self-administration in the C57BL/6J mouse. Neuroreport 1991;2:477-80.
24. Ranaldi R, Poeggel K. Baclofen decreases methamphetamine self-administration in rats. Neuroreport 2002;13: 1107-10.
25. Ranaldi R, Anderson KG, Carroll FI, Woolverton WL. Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: interaction with methamphetamine. Psychopharmacology (Berl) 2000; 153:103-10.
26. Anggadiredja K, Sakimura K, Hiranita T, Yamamoto T. Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward. Brain Res 2004;1021:272-6.
27. Davidson C, Lee TH, Ellinwood EH. Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem Int 2005;46:189-203.
28. Clemens KJ, Cornish JL, Hunt GE, McGregor IS. Intravenous methametamine self-administration in rats: effects of intravenous or intraperitoneal MDMA coadministration. Pharmacol Biochem Behav 2006; Nov 14 [Epub ahead of print].
29. Munzar P, Baumann MH, Shoaib M, Goldberg SR. Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats. Psychopharmacology (Berl) 1999;141:287-96.
30. Piasecki MP, Steinagel GM, Thienhaus OJ, Kohlenberg BS. An exploratory study: the use of paroxetine for methamphetamine craving. J Psychoactive Drugs 2002;34: 301-4.
31. Degenhardt L, Barker B, Topp L. Patterns of ecstasy use in Australia: findings from a national household survey. Addiction 2004;99:187-95.
32. Robledo P, Balerio G, Berrendero F, Maldonado R. Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn Schmiedebergs Arch Pharmacol 2004;369:338-49.
33. Morley KC, Arnold JC, McGregor IS. Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2005;29: 648-57.
34. Stephenson CP, Hunt GE, Topple AN, McGregor IS. The distribution of 3,4-methylenedioxymethamphetamine 'Ecstasy'-induced c-fos expression in rat brain. Neuroscience 1999;92:1011-23.
35. Wolff K, Tsapakis EM, Winstock AR, et al. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol 2006; 20:400-10.
36. Battaglia G, Yeh SY, De Souza EB. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 1988;29:269-74.
37. Sprague JE, Everman SL, Nichols DE. An integrated hypothesis for the serotonergic axonal loss induced by 3,4- methylenedioxymethamphetamine. Neurotoxicology 1998; 19:427-441.
38. McGregor IS, Clemens KJ, Van Der Plasse G, et al. Increased anxiety 3 months after brief exposure to MDMA ('Ecstasy' in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 2003;28: 1472-84.
39. Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ('ecstasy'). Eur J Pharmacol 2001;433:91-9.
40. Johnson M, Hanson GR, Gibb JW. Effects of dopaminergic and serotonergic receptor blockade on neurochemical changes induced by acute administration of methamphetamine and 3,4-methylenedioxymethamphetamine. Neuropharmacology 1988;27:1089-96.
41. Kokoshka JM, Metzger RR, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Res 1998;799:78-83.
42. Cadet JL, Jayanthi S, Deng X. Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 2003; 17:1775-88.
43. Cadet JL, Jayanthi S, Deng X. Methamphetamineinduced neuronal apoptosis involves the activation of multiple death pathways. Review. Neurotox Res 2005;8: 199-206.
44. Abekawa T, Ohmori T, Honda M, Ito K, Koyama T. Effect of low doses of L-NAME on methamphetamine-induced dopaminergic depletion in the rat striatum. J Neural Transm 2001;108:1219-30.
45. Cappon GD, Morford LL, Vorhees CV. Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response. Brain Res Dev Brain Res 1997; 103:155-62.
46. Villemagne V, Yuan J, Wong DF, et al. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 1998;18:419-27.
47. Pubill D, Canudas AM, Pallas M, Camins A, Camarasa J, Escubedo E. Different glial response to methamphetamineand methylenedioxymethamphetamine- induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 2003;367: 490-9.
48. Imam SZ, Ali SF. Aging increases the susceptibility to methamphetamine-induced dopaminergic neurotoxicity in rats: correlation with peroxynitrite production and hyperthermia. J Neurochem 2001;78:952-9.
49. Burrows KB, Gudelsky G, Yamamoto BK. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4- methylenedioxymethamphetamine administration. Eur J Pharmacol 2000;398:11-8.
50. Clemens KJ, Cornish JL, Li KM, Hunt GE, McGregor IS. MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and longterm adverse effects in female rats. Neuropharmacology 2005;49:195-207.
51. Clemens KJ, Van Nieuwenhuyzen PS, Li KM, Cornish JL, Hunt GE, McGregor IS. MDMA ('ecstasy'), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl) 2004;173:318-25.
52. Bull EJ, Hutson PH, Fone KC. Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT(2A) receptor responsivity. Neuropharmacology 2004;46:202-10.
53. McGregor IS, Gurtman CG, Morley KC, et al. Increased anxiety and 'depressive' symptoms months after MDMA ('ecstasy') in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology (Berl) 2003;168: 465-74.
54. Williams MT, Morford LL, Wood SL, et al. Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res 2003;968: 89-101.
55. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV. 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 2001;21:3228-35.
56. Timar J, Gyarmati S, Szabo A, Furst S. Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives. Behav Pharmacol 2003; 14:199-206.
57. Byrne T, Baker LE, Poling A. MDMA and learning: effects of acute and neurotoxic exposure in the rat. Pharmacol Biochem Behav 2000;66:501-8.
58. Bisagno V, Ferguson D, Luine VN. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res 2002;940:95-101.
59. Chapman DE, Hanson GR, Kesner RP, Keefe KA. Longterm changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J Pharmacol Exp Ther 2001;296:520-7.
60. Friedman SD, Castaneda E, Hodge GK. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamineinduced neurotoxicity. Pharmacol Biochem Behav 1998; 61:35-44.
61. Guillot C, Greenway D. Recreational ecstasy use and depression. J Psychopharmacol 2006;20:411-6.
62. Parrott AC. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 2006;20:147-63.
63. Thomasius R, Zapletalova P, Petersen K, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 2006;20:211-25.
64. London ED, Berman SM, Voytek B, et al. Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry 2005;58:770-8.
65. Chang L, Cloak C, Patterson K, Grob C, Miller EN, Ernst T. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol Psychiatry 2005;57:967-74.
66. Chang L, Ernst T, Speck O, et al. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res 2002;114:65-79.
67. Thompson PM, Hayashi KM, Simon SL, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 2004;24:6028-36.
68. Gurtman CG, Morley KC, Li KM, Hunt GE, McGregor IS. Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol 2002;446:89-96.
69. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol 2002;135:170-80.
70. Clemens KJ, Cornish JL, Hunt GE, McGregor IS. Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. Drug Alcohol Depend 2007;86: 183-90.